/ACHFF
ACHFF Stock - Arch Biopartners Inc.
Healthcare|BiotechnologyOTC
$0.89-2.54%
$0.02 (-2.54%) • Dec 19
53
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.40
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.42
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.97
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ACHFF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.88 – $0.89
TARGET (TP)$1.02
STOP LOSS$0.82
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.96
52W High$1.42
52W Low$0.65
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.12M | $1.98M | $964,681 | $3.89M | $67,886 |
| Gross Profit | $-1,656,000 | $-129,000 | $-503,000 | $-150,000 | $-2,123,000 |
| Gross Margin | -78.0% | -6.5% | -52.1% | -3.9% | -3127.3% |
| Operating Income | $-3,947,113 | $-3,355,000 | $-1,389,000 | $-1,165,000 | $-4,634,000 |
| Net Income | $-3,920,000 | $-3,327,000 | $-1,408,000 | $-1,170,000 | $-4,629,000 |
| Net Margin | -184.7% | -167.7% | -146.0% | -30.1% | -6818.8% |
| EPS | $-0.06 | $-0.05 | $-0.02 | $-0.02 | $-0.08 |
Company Overview
Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ACHFFBeat Rate
42%
Last 12 quarters
Avg Surprise
-6.9%
EPS vs Estimate
Beats / Misses
5/5
2 met exactly
Latest EPS
$-0.00
Q3 2025
EPS Surprise History
Q1 24
-100.0%
$-0.01vs$-0.00
Q2 24
0.0%
$-0.01vs$-0.01
Q3 24
-49.9%
$-0.01vs$-0.01
Q3 24
-33.9%
$-0.01vs$-0.01
Q1 25
+69.9%
$-0.00vs$-0.01
Q1 25
+51.4%
$-0.01vs$-0.01
Q2 25
+80.6%
$-0.00vs$-0.01
Q3 25
+80.0%
$-0.00vs$-0.01
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 28, 2026 | — | — | — | — |
Q1 2026 | Jan 27, 2026 | — | — | — | — |
Q3 2025 | Sep 2, 2025 | $-0.01 | $-0.00 | +80.0% | ✓ BEAT |
Q2 2025 | May 30, 2025 | $-0.01 | $-0.00 | +80.6% | ✓ BEAT |
Q1 2025 | Mar 3, 2025 | $-0.01 | $-0.01 | +51.4% | ✓ BEAT |
Q1 2025 | Jan 27, 2025 | $-0.01 | $-0.00 | +69.9% | ✓ BEAT |
Q3 2024 | Sep 3, 2024 | $-0.01 | $-0.01 | -33.9% | ✗ MISS |
Q3 2024 | Aug 29, 2024 | $-0.01 | $-0.01 | -49.9% | ✗ MISS |
Q2 2024 | May 30, 2024 | $-0.01 | $-0.01 | 0.0% | = MET |
Q1 2024 | Jan 29, 2024 | $-0.00 | $-0.01 | -100.0% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | $-0.02 | $0.00 | +119.1% | ✓ BEAT |
Q3 2023 | Aug 29, 2023 | $-0.01 | $-0.01 | -49.9% | ✗ MISS |
Q1 2023 | Mar 1, 2023 | $-0.01 | $-0.04 | -250.0% | ✗ MISS |
Q1 2023 | Jan 31, 2023 | $-0.01 | $-0.01 | 0.0% | = MET |
Q3 2022 | Aug 30, 2022 | — | $-0.01 | — | — |
Q2 2022 | May 31, 2022 | — | $-0.00 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.01 | — | — |
Q1 2022 | Jan 22, 2022 | — | $-0.00 | — | — |
Q3 2021 | Sep 30, 2021 | — | $0.01 | — | — |
Q2 2021 | Jun 30, 2021 | — | $0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ACHFF
What is ACHFF's current stock price?
Arch Biopartners Inc. (ACHFF) is currently trading at $0.89 per share. The stock has moved -2.54% today.
What is the analyst price target for ACHFF?
No analyst price targets are currently available for this stock.
What sector is Arch Biopartners Inc. in?
Arch Biopartners Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is ACHFF's market cap?
Arch Biopartners Inc. has a market capitalization of $0.06 billion, making it a small-cap company.
Does ACHFF pay dividends?
No, Arch Biopartners Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCVALF
Covalon Technologies Ltd.
$1.25
Mkt Cap: $0.0B
HBPCF
Helix BioPharma Corp.
$1.73
Mkt Cap: $0.1B
INNMF
Amplia Therapeutics Limited
$0.08
Mkt Cap: $0.0B
OTLC
Oncotelic Therapeutics, Inc.
$0.09
Mkt Cap: $0.0B
PSYBF
PsyBio Therapeutics Corp.
$0.00
Mkt Cap: $0.0B
RLFTF
Relief Therapeutics Holding AG
$2.70
Mkt Cap: $0.0B
RLFTY
MindMaze Therapeutics Holding S.A. Sponsored ADR
$3.65
Mkt Cap: $0.0B
SPBBF
Speakeasy Cannabis Club Ltd.
$0.00
Mkt Cap: $0.0B
VICP
Vicapsys Life Sciences, Inc.
$1.50
Mkt Cap: $0.0B
ZIVO
ZIVO Bioscience, Inc.
$9.98
Mkt Cap: $0.0B
Explore stocks similar to ACHFF for comparison